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It is commonly believed by oncologists that anthracycline-
containing regimens are the most effective combinations for the
management of patients with breast cancer. Anthracycline-
containing regimens represent the treatment of choice for adjuvant
or neoadjuvant chemotherapy (Hortobagyi et al, 1991, 1993,
1995), and produce the highest objective response rates in
metastatic breast cancer (Henderson, 1991). Unfortunately,
however, anthracycline-containing chemotherapy regimens are
(or become) ineffective in many patients.
Resistance of human breast cancers to anthracyclines results
from the acquisition or pre-existence of several drug resistance
mechanisms, including: reduction of the fluidity of the cell
membrane, increase in the effectiveness of DNA repair mecha-
nisms, multidrug resistance with overexpression of the Gp170
membrane glycoprotein, or modification of topoisomerase II
activity (De Vita, 1993). These mechanisms of drug resistance are
common to most chemotherapy agents. For this reason the pres-
ence of anthracycline resistance might indicate that no cytotoxic
drug will have satisfactory results.
Several new cytotoxic agents, however, have been demonstrated
to have definite anti-tumour effects in anthracycline-resistant
tumours. This exciting characteristic is shared by mitomycin, most
of the vinca alkaloids, including vinorelbine, and the most recently
developed family of drugs with marked anti-tumour activity
against breast cancer, the taxoids. A rapid overview of the results
of these new chemotherapy agents in patients with breast cancer
supports the observation that these drugs are useful for the treat-
ment of anthracycline-resistant tumours. Table 1 reports published
definitions of anthracycline-resistant breast cancer.
The criteria used to define anthracycline resistance among these
trials varied. Therefore, it is difficult to determine the efficacy of
these drugs in anthracycline-resistant tumours and to compare the
relative activity of these drugs. The most stringent definition of
anthracycline resistance was absence of response to a first- or a
second-line anthracycline-containing regimen, or relapse during
anthracycline-containing adjuvant or neoadjuvant chemotherapy
(primary resistance). Secondary resistance was defined as an
initial response followed by progressive disease during treatment
with first- or second-line anthracycline-containing regimen,
(Ravdin et al, 1995; Valero et al, 1995; Vermorken et al, 1995).
However, other published definitions included not only progres-
sive disease during anthracycline-containing chemotherapy, but
also cases in which disease recurrence was detected within 6 or
12 months or even later after completion of adjuvant, neoadjuvant,
or first-line metastatic anthracycline-containing regimen (Creech
et al, 1983; Yau et al, 1985; Walter et al, 1992; Holmes et al, 1993;
Nabholtz et al, 1993; Seidman et al, 1993; Degardin et al, 1994;
Munzone et al, 1994; Wilson et al, 1994; Jones et al, 1995).
The major objective of the study reported here was to propose a
unified clinical definition of anthracycline resistance in breast
cancer.
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Summary The purpose of the study was to determine the response rates (RR) and duration to second- and third-line chemotherapy
programmes in patients with anthracycline-resistant breast cancer, utilizing various definitions of anthracycline resistance. This was a
retrospective analysis performed on 1335 patients with metastatic breast cancer who participated in consecutive clinical trials of first line,
anthracycline-containing combination chemotherapy (ACCC) at the University of Texas MD Anderson Cancer Center between July 1973 and
April 1980. Anthracycline-resistant groups were identified using definitions of anthracycline resistance found in the literature: progressive
disease as best response to ACCC (Group 1, n = 56 patients); progressive disease while receiving ACCC after an intervening response to the
drug (Group 2, n = 84); progressive disease within 6 months of last dose of ACCC (Group 3, n = 233); and progressive disease within
12 months of last dose of ACCC (Group 4, n = 272). Second- and third-line therapies administered to these patients included methotrexate,
doxorubicin, mitoxantrone, bisantrene, vinblastine, vindesine, melphalan, mitomycin, cisplatin, etoposide and others, but not taxanes. The
distribution of patients’ characteristics was similar between the four groups, as was the use of second- and third-line regimens. Response rate
(RR) to second-line chemotherapy were 5% and 7.7% for Group 1 and Group 2 respectively. In contrast, RR to second-line chemotherapy
were 21.6% and 15% for Group 3 and 4. The differences in response rate between the combination of Groups 1 and 2 and Groups 3 or 4 were
significant (P = 0.005 and P = 0.04 respectively). These results indicate that strictly defined anthracycline resistance as defined in Groups 1
and 2 is associated with resistance to many other cytotoxic drugs. The definitions used in Groups 3 and 4 include many patients with
responsive tumours, and a more favourable prognosis. © 2000 Cancer Research Campaign
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This study included 1335 patients treated at the University of
Texas MD Anderson Cancer Center between July 1973 and April
1980 with an anthracycline-containing regimen as first-line
chemotherapy for metastatic breast cancer. A complete description
of this patient population has previously been reported
(Hortobagyi et al, 1983).
Second- and third-line chemotherapy regimens included cyto-
toxic agents such as doxorubicin, methotrexate, vincristine,
vinblastine, vindesine, mitoxantrone, bisantrene, melphalan, mito-
mycin C, cisplatin, etoposide, teniposide, peptichimio, pentostatin,
anguidine, AMSA, 5-fluorouracil, L-asparginase and other less
effective agents. At the time these patients were treated drugs such
as vinorelbine, paclitaxel and docetaxel had not reached clinical
trials. Within the study population, we defined four subgroups of
patients with anthracycline-resistant disease according to the
various definitions of anthracycline-refractory breast cancer found
in the literature.
Definitions of anthracycline resistance
The most stringent definition of anthracycline resistance in the
literature was absence of response to a first- or a second-line
anthracycline-containing regimen (disease progression, or stable
disease followed by disease progression), or relapse while 
adjuvant or neoadjuvant anthracycline-containing chemotherapy.
This type of resistance was referred to as ‘primary anthracycline
resistance’.
Secondary resistance was defined as initial response followed
by progressive disease while receiving first- or second-line anthra-
cycline-containing chemotherapy.
In other published reports, less stringent criteria of anthracy-
cline resistance were used. Some reports included not only patients
with no response or progressive disease during anthracycline-
containing treatment but also patients who had progressive disease
within 6 or even 12 months after completion of neoadjuvant,
or adjuvant therapy, or first-line anthracycline-containing
chemotherapy for metastatic disease.
Definition of objective response
A complete response included the disappearance of all measurable
and assessable disease, with no new lesion. Partial response was
applied to patients with a decrease greater than or equal to 50% of
measurable lesions with no progression of assessable disease and
no new lesion. Responders combined patients who achieved
complete response or partial response.
Characteristics of patient subgroups
Of the 1335 patients in this study, 74 (5.5%) died during adminis-
tration of the anthracycline-containing regimen. These patients
were excluded from the analysis. The median follow-up for the
study population was 27.5 months (range 3–255 months).
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Table 1 Studies evaluating efficacy of cytotoxic agents in anthracycline-resistant breast cancer
Reference Agent Number of patients Definition of anthracycline resistance
Valero Docetaxel 34 PD during ACR
Ravdin Docetaxel 35 PD during ACR
Vermorken Paclitaxel 36 PD during ACR
Seidman Paclitaxel 49 PD during ACR
Munzone Paclitaxel 50 PD during or within 12 months after ACR
Holmes Paclitaxel 18 PD during ACR
Wilson Paclitaxel 33 PD during or within 16 months after ACR
Nabholtz Paclitaxel 96 PD during or within 6 months after ACR
Jones Vinorelbine 115 PD during or any time after ACR
Degardin Vinorelbine 100 PD during or any time after ACR
Yau Vindesin 61 PD during or any time after ACR
Yau Vinblastine 23 PD during or any time after ACR
Walters Mitolycin 67 PD during or any time after ACR
Creech Mitolycin 90 PD during or any time after ACR
ACR = anthracycline-containing regimen; PD = progressive disease.
Table 2 Number of patients treated with second- or third-line chemotherapy according to various definitions of anthracycline
resistance among 1335 patients with metastatic breast cancer treated with first-line ACR
Number of patients treated with
Number of Second-line Third-line
Definition of anthracycline resistance patients chemotherapy chemotherapy
Primary resistance (PD during ACR with no 56 40 14
intervening response)
Secondary resistance (PD during ACR with 84 65 26
intervening response)
Primary + secondary resistance 140 105 40
PD within 6 months after last dose of ACR 233 102 49
PD between 6 and 12 months after last dose
of ACR 272 126 50
ACR: anthracycline-containing regimen; PD: progressive disease.Fifty-six of the 1335 patients in the study (4.2%) had primary
anthracycline resistance, and 84 patients (6.3%) had secondary
anthracycline resistance. An additional 233 patients (17.5%) had
progressive disease within 6 months of completion of an anthracy-
cline-containing regimen, and an additional 272 patients (20.4%)
had disease progression between 6 and 12 months after the last
dose of an anthracycline-containing regimen. The number of
patients in each of these subgroups who received second- or third-
line chemotherapy is given in Table 2.
Other characteristics of each subgroup are given in Table 3. The
patients included in this analysis received no adjuvant or neoadju-
vant treatment, and the distribution of first-line chemotherapy
programmes and number and type of systemic treatments that
patients received after first-line anthracycline-containing regimens
were similar in each subgroup.
Statistical analysis
For each of the four subgroups, the response rate (RR) to second-
and third-line chemotherapy regimens were available. A comparison
between the four subgroups was performed using the c2test. The RR
for each group were also combined with the aim of describing a
population similar to the one selected by previous authors.
The overall survival was measured from the date of progression
on anthracycline-containing therapy until death from any cause, or
until the date of last follow-up for patients still alive. The length of
progression-free survival was defined at the time from initiation of
chemotherapy to the time of documented disease progression.
Curves plotting the distribution of disease-free and overall survival
times were calculated by the method of Kaplan and Meier (1958),
and differences among distributions were tested using the log-rank
test (Mantel, 1966). P-values of 0.05 or less were considered
statistically significant and strong statistical evidence against the
null hypothesis.
RESULTS
There were no differences in the distribution of patients’ character-
istics between the four subgroups analysed. The types of first-line
anthracycline-containing regimens, and the number and type of
salvage treatment used after first-line chemotherapy were similar
in all four groups.
Table 4 reports the RR by line of chemotherapy for each
subgroups. In the subgroup of patients with stringently defined
primary or secondary anthracycline-resistant breast cancer, the RR
to second- and third-line chemotherapy were 6.7% (7/105), and
7.5% (3/40) respectively.
Among patients who had recurrent disease within 6 months 
after completion of a first-line anthracycline-containing regimen
(excluding patients with primary or secondary anthracycline-
resistant breast cancer), the RR after second- and third-line
chemotherapy were 21.6% (22/102), and 14.3% (7/49) respec-
tively. The differences in RR between this third group and the
combination of the two prior groups were statistically significant
for second-line chemotherapy (P = 0.005), but not significant for
third-line chemotherapy (P = 0.3).
Among patients with a relapse that occurred between 6 and 12
months after completion of first-line chemotherapy. The RR
reported for second- and third-line chemotherapy were 15%
(19/126), and 12% (6/50) respectively. Again, the differences in
RR between this group and the combination of the first two groups
(primary and secondary anthracycline-resistance) were statisti-
cally significant (P = 0.04) for second-line chemotherapy, but not
for third-line chemotherapy (P = 0.5).
The RR achieved by second- and third-line chemotherapy in the
subgroup of patients who recurred within 6 months and between 6
and 12 months after completion of first-line chemotherapy were
not statistically different (P = 0.2 and P = 0.8 respectively). To
select a population comparable to those utilized in other published
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Table 3 Patient characteristics and survival experience of patients with anthracycline-resistant breast cancer according to different definitions of anthracyline-
resistance
Definition of anthracycline resistance
Progression/relapse Progression/relapse
Primary+ within 6 months after 6 to 12 months after
Patient characteristics Primary Secondary secondary last dose of last dose of
anthracycline therapy anthracycline therapy
Number of patients 56 84 140 233 272
Stage IV at presentation 8 (14%) 16 (19%) 24 (17%) 35 (15%) 48 (17.6%)
Madian age at diagnosis (range) 51 (24–74) 48 (24–77) 49 (24–77) 49 (25–79) 49 (25–78)
Madian age at recurrence (range) 53 (25–75) 53 (24–79) 53 (24–79) 52 (26–79) 53 (25–79)
Median DFI in months (range) 18 (1–144) 27,5 (2–191) 23 (1–191) 17,5 (1–360) 24 (1–275)
Median OS from diagnosis in 28 (6–365) 46 (7–231) 39 (6–365) 35 (7–410) 42 (12–397)
months (range)
Median OS from recurrence 14 (3–273) 20 (6–141) 18 (3–273) 19 (7–235) 25 (12–259)
in months (range)
Metastatic site
CNS 0 0 0 4 (1.7%) 2 (0.7%)
Bone 20 (35.7%) 39 (46.4%) 59 (42.1%) 74 (31.8%) 126 (46.3%)
Lung 13 (23.2%) 37 (44%) 50 (35.7%) 53 (22.7%) 82 (30.1%)
Liver 7 (12.5%) 14 (16.6%) 21 (15%) 24 (10.3%) 38 (14%)
Soft-tissues 20 (35.7%) 42 (50%) 62 (44.3%) 116 (49.8%) 110 (40.5%)
CNS: central nervous system; DFI: disease-free interval; OS: overall survival.studies of anthracycline-resistant breast cancer, we have to
combine the results of the first three subgroups or the results of all
four subgroups (Table 4). It is evident that the inclusion of patients
who developed progressive disease up to 6 or 12 months after the
last dose of anthracycline considerably improves response rates to
second- and third-line therapies.
There was a statistically significant difference in survival
(P < 0.01) from the date of progression among the three subgroups
(Figure 1). Survival at 1, 2 and 3 years from the date of progres-
sion on (or after) anthracycline-containing therapy for the four
groups is given on Table 5.
DISCUSSION
According to the definitions of anthracycline resistance in the
literature, we selected four subgroups for analysis from our data-
base of 1335 patients treated in prospective clinical trials of
anthracycline-containing first-line chemotherapy for metastatic
breast cancer. No differences were noted in terms of patient and
treatment characteristics between these four subgroups and the
total group of 1335 (Hortobagyi et al, 1983).
For the groups of patients whose relapses occurred within
6 months or between 6 and 12 months after completion of an
anthracycline-containing regimen, the RR to second- (21.5% and
15%) and third-line (14.3% and 12%) chemotherapy were similar
between the two subgroups and consistent with the results in the
literature for patients previously treated (but not necessarily resis-
tant to) with chemotherapy. In the literature, RR reported for
second- or third-line chemotherapy for metastatic breast cancer are
between 17% and 54% (Hortobagyi et al, 1995), depending on the
type of chemotherapy used; the mean RR for second- or third-line
chemotherapy without an anthracycline is 20%. Moreover, the RR
to second- (21.5% and 15%) and third-line chemotherapy (14.3%
and 12%) found in these subgroups with loosely defined anthracy-
cline resistance, were not different from the rate reported for the
rest of the total group of 1335 patients (21.7% and 14.4% respec-
tively, for second- and third-line chemotherapy).
The anthracycline-resistant phenotype requires several non-
specific mechanisms of resistance. As a consequence, the lack of
efficacy of an anthracycline-containing regimen predicts a reduc-
tion in the efficacy for most other chemotherapy drugs. Disease
relapse within 12 months after the completion of anthracycline
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Table 5 Survival of patients with anthracycline-resistant breast cancer according to the various definitions of resistance
Anthracycline-resistant subgroup Median survival (range) Survival (s.e.) (%)
1-year 2-year 3-year
Primary resistance + secondary 5 months (1–78) 21% (4%) 9% (4%) 1% (2%)
resistance subgroup
PD within 6 months after last dose of ACR 9 months (0–198) 35% (3%) 13% (3%) 6% (2%)
PD between 6 to 12 months after last 11 months (1–201) 39% (3%) 14% (3%) 7% (2%)
dose of ACR
PD: progressive disease; s.e.: standard error; ACR: anthracycline-containing regimen.
Table 4 Response rates for second- and third-line chemotherapy according to definition of anthracycline resistance
Definition of anthracycline resistance Objective responses (%) for
Second-line chemotherapy Third-line chemotherapy
Primary resistance (PD during ACR with 5% (Cl: 6.7%) (2/40) 7.1% (Cl: 13.5%) (1/14)
no intervening response)
Secondary resistance (PD during ACR 7.7% (Cl: 6.5%) (5/65) 7.7% (Cl: 10%) (2/26)
with intervening response)
Primary + secondary resistance 6.7% (Cl: 4.8%) (7/105) 7.5% (Cl: 8.2%) (3/40)
PD within 6 months after last dose of ACR 21.6% (Cl: 8%) (22/102) 14.3% (Cl: 9.8%) (7/49)
PD between 6 and 12 months after last 15% (Cl: 6.2%) (19/126) 12% (Cl: 9%) (6/50)
dose of ACR
No anthracycline resistance 21.7% (Cl: 4.4%) (75/345) 14.3% (Cl: 5.8%) (21/144)
ACR: anthracycline-containing regimen; PD: progressive disease.
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Figure 1 Survival from progression on an anthracycline-containing regimen
until death or date of last follow-uptreatment may represent partial resistance to anthracyclines and
other agents, or may indicate kinetic characteristics of the disease
that would result in accelerated regrowth after effective
chemotherapy. However, patients with disease relapse within
12 months after anthracycline-containing chemotherapy do not
represent a specific population with strong chemotherapy-resistant
characteristics. This finding is also consistent with the fact that the
RR in these two groups were not different from those expected or
obtained in the overall population studied. It seems reasonable not
to consider these two patient subgroups as having anthracycline-
resistant breast cancer.
Recurrence or metastases that occurred shortly (within months)
after completion of therapy, are probably a sign of reduced
efficacy of the anthracycline-containing regimen, or an indication
of a particularly aggressive and rapidly growing tumour. These
characteristics do not preclude sensitivity to anthracyclines, and
does not represent proof of anthracycline-resistance.
The patients defined as having primary and secondary anthracy-
cline resistance exhibited significantly lower rates of RR after
second-line (6.7%) or after third-line chemotherapy (7.5%). These
RR were statistically lower for the second-line chemotherapy than
those obtained in the rest of the population after similar salvage
therapies. The differences in RR at third-line chemotherapy were
not found to be statistically significant, probably related to smaller
sample size inducing lower power and less precise estimates.
Therefore, it seems that the definition of anthracycline resistance
that includes only progressive disease during treatment with an
anthracycline selects a very unfavourable group, that is clearly less
responsive to other chemotherapy regimens and reflects true
anthracycline resistance.
This study included only patients with metastatic breast cancer
treated with an anthracycline-containing regimen; however, the
criteria for same anthracycline resistance could probably be
extended to patients receiving anthracycline-containing adjuvant
and neoadjuvant treatment. In these cases, our definition would
indicate that relapse that occurred within 6 or 12 months of the last
dose of anthracycline therapy is not a marker of anthracycline
resistance, and only progressive disease during a neoadjuvant 
or adjuvant anthracycline-containing regimen is an acceptable
indicator to identify anthracycline resistance.
These results apply to cytotoxic agents available during the
study period. Response to newer, and possibly more effective,
agents, such as taxanes (Pivot et al, 1999) will need to be exam-
ined prospectively, preferably with a clear definition of anthracy-
cline-resistant populations treated.
CONCLUSION
A clinical definition of anthracycline-refractory breast cancer that
includes only patients with progressive disease during anthracy-
cline chemotherapy seems to determine a very unfavourable
subset, that is significantly less sensitive to other chemotherapy
agents. All other definitions with broader inclusion criteria appear
to determine populations that will have response rates similar to
those achieved by the total population with metastatic breast
cancer. To determine the real activity of cytotoxic drugs in anthra-
cycline-resistant breast cancer, all previously reported studies that
have analysed drug activity against anthracycline-resistant breast
cancer may need to be re-evaluated.
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